Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer

Ning Zhu, Jing Zhang, Yuping Du, Xiaodong Qin, Ruidong Miao, Jing Nan, Xing Chen, Jingjie Sun, Rui Zhao, Xinxin Zhang, Lei Shi, Xin Li, Yuxi Lin, Wei Wei, Aihong Mao, Zhao Zhang, George R. Stark, Yuxin Wang, Jinbo Yang

Producción científica: Articlerevisión exhaustiva

20 Citas (Scopus)


Tamoxifen, a widely used modulator of the estrogen receptor (ER), targets ER-positive breast cancer preferentially. We used a powerful validation-based insertion mutagenesis method to find that expression of a dominant-negative, truncated form of the histone deacetylase ZIP led to resistance to tamoxifen. Consistently, increased expression of full-length ZIP gives the opposite phenotype, inhibiting the expression of genes whose products mediate resistance. An important example is JAK2. By binding to two specific sequences in the promoter, ZIP suppresses JAK2 expression. Increased expression and activation of JAK2 when ZIP is inhibited lead to increased STAT3 phosphorylation and increased resistance to tamoxifen, both in cell culture experiments and in a mouse xenograft model. Furthermore, data from human tumors are consistent with the conclusion that decreased expression of ZIP leads to resistance to tamoxifen in ERpositive breast cancer.

Idioma originalEnglish (US)
Páginas (desde-hasta)15047-15054
Número de páginas8
PublicaciónProceedings of the National Academy of Sciences of the United States of America
EstadoPublished - jun 30 2020
Publicado de forma externa

ASJC Scopus subject areas

  • General


Profundice en los temas de investigación de 'Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer'. En conjunto forman una huella única.

Citar esto